Lymphomas Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings

Data from the following clinical trials are discussed:

• ASCO 7521: ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
• EHA P1120: The Efficacy and Safety of Zanubrutinib and Dexamethasone in Symptomatic Waldenstrom Macroglobulinemia
• EHA P1160: Results of a Phase 2 Expanded Access Study of Zanubrutinib in Patients with Waldenstrom Macroglobulinemia
• ASCO 7510: Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial
• ASCO 7511: Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL
• ASCO 7524: Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial